Compare Ascendis Pharma A/S (ASND) vs Iris Energy Limited (IREN) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

IREN trades at $41.11, down 1.46% on the day, amid a bearish technical signal with key support at $40. The company is transitioning from Bitcoin mining to AI infrastructure, with revenue growing from $501M in 2025 to a projected $757M in 2026. Recent earnings have missed expectations, but analyst sentiment remains largely positive with a consensus price target of $79.11, representing significant upside potential from current levels.

The outlook hinges on successful execution of its AI cloud strategy, with a $3.1B contracted ARR target by end-2026 being a key catalyst. However, risks include intense competition, high capital expenditure evidenced by negative investing cash flow, and recent earnings misses. The stock offers high growth potential but carries substantial execution risk.